. 2019 May 8;10(9):1531–1549. doi: 10.1039/c9md00169g

Table 2. Arylboronic acid based-prodrugs 14–26.


Cpd.	Drug/active species	Indication	In vitro efficacy	In vivo studies	Group	Ref.
14–17, 20	QM, aminoferrocenium/Fe²⁺	Cancer	Cytotoxicity against human promyelocytic leukemia (HL-60), human glioblastoma-astrocytoma (U373), chronic lymphocytic leukemia (CLL), lymphoma (BL-2), ovarian (A2780) and prostate cancer (LNCaP and DU-145) cells	Efficacy studies on mice carrying L1210 leukemia, in a prostate cancer (LNCaP) xenograft murine model and inhibition of growth of Guerin's carcinoma (T8). Accumulation in ascites of NK/Ly-lymphoma mice	A. Mokhir	43–49
14–17, 20	QM, aminoferrocenium/Fe²⁺	Cancer		Preliminary toxicity evaluation in treated mice, acute toxicity in rats and mice for a 21 day treatment. Ex vivo toxicity in the liver	A. Mokhir	43–49
18–19	QM, aminoferrocenium/Fe²⁺, and Pt(ii) complexes	Cancer	Cytotoxicity against ovarian cancer cell lines A2780 and cisA2780	—	A. Mokhir	50, 51
21–24, 26	4-OHT, endoxifen, and GWK7604	Cancer	Cytotoxicity against breast (MCF-7 and T47D) cancer cells	Efficacy in a breast cancer (MCF-7) xenograft mouse model and acute toxicity in treated animals pharmacokinetic studies in mice	G. Wang	52–54
25	Fulvestrant	Cancer	Inhibition of cell proliferation in MCF-7 and T47D cells	Efficacy in MCF-7 xenograft and patient derived xenograft (PDX) mouse models. Preliminary toxicity evaluation in treated mice metabolism and pharmacokinetic studies in mice	G. Wang	55, 56